|
1.
|
|
19 p, 7.4 MB |
Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma
/
Caillot, Mélody (Normandie Université) ;
Miloudi, Hadjer (Normandie Université) ;
Taly, Antoine (IPSL Research University) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana C. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribeiro, Marcelo L. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Maitre, Elsa (CHU Côte de Nacre) ;
Saule, Simon (Université Paris-Sud) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jardin, Fabrice (Centre de lutte contre le cancer Henri Becquerel) ;
Sola, Brigitte (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Miloudi, Hadjer (Normandie Université)
Exportin 1 (XPO1) is the main nuclear export receptor that controls the subcellular trafficking and the functions of major regulatory proteins. XPO1 is overexpressed in various cancers and small inhibitors of nuclear export (SINEs) have been developed to inhibit XPO1. [...]
2023 -  10.1002/1878-0261.13386
Molecular Oncology, Vol. 17 Núm. 12 (december 2023) , p. 2546-2564
|
|
|
2.
|
|
29 p, 401.7 KB |
Epigenetic targets in B- and T-cell lymphomas : latest developments
/
Ribeiro, Marcelo L. (Sao Francisco University Medical School) ;
Sánchez Vinces, Salvador (Sao Francisco University Medical School) ;
Mondragón, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Non-Hodgkin's lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or stem cell transplantation, relapsed and/or refractory cases still have a dismal outcome. [...]
2023 - 10.1177/20406207231173485
Therapeutic Advances in Hematology, Vol. 14 (1-12 2023)
|
|
|
3.
|
|
|
4.
|
|
20 p, 1.1 MB |
RHOA Therapeutic Targeting in Hematological Cancers
/
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez Vinces, Salvador (Sao Francisco University Medical School, São Paulo, Brazil) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival, migration, adhesion and proliferation. [...]
2023 - 10.3390/cells12030433
Cells, Vol. 12 Núm. 3 (february 2023) , p. 433
|
|
|
5.
|
|
12 p, 2.5 MB |
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice
/
Galindo Campos, Miguel A. (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Lutfi, Nura (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Bonnin, Sarah (Centre de Regulació Genòmica) ;
Martínez Cáceres, Carlos (Instituto Murciano de Investigación Biosanitaria-Laboratorio de Investigación Biosanitaria-Arrixaca) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Hernández, Violeta (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Martín Caballero, Juan (Instituto Cajal. Consejo Superior de Investigaciones Científicas (CSIC)) ;
Ampurdanés, Coral (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Gimeno, Ramón (Laboratory of Immunology. Department of Pathology) ;
Colomo, Lluís (Hospital del Mar (Barcelona, Catalunya)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guilbaud, Guillaume (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Dantzer, Françoise (Biotechnology and Cell Signaling. Unité Mixte de Recherche (UMR) 7242 Centre National de la Recherche Scientifique. Laboratory of Excellence Medalis. École Supérieure de Biotechnologie de Strasbourg. Strasbourg University) ;
Navarro, Pilar (Hospital del Mar Medical Research Institute. Unidad Asociada IIBB-CSIC) ;
Murga, Matilde (Genomic Instability Group. Spanish National Cancer Research Centre) ;
Fernández Capetillo, Oscar (Science for Life Laboratory. Department of Medical Biochemistry and Biophysics. Karolinska Institutet) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sale, Julian E. (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Yélamos, José (Laboratory of Immunology. Department of Pathology)
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. [...]
2022 - 10.1182/blood.2021012805
Blood, Vol. 139 Núm. 2 (13 2022) , p. 228-239
|
|
|
6.
|
|
30 p, 7.3 MB |
Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
/
Campillo-Marcos, Ignacio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Casado Pelaez, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mata, Caterina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mereu, Elisabetta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ;
Molero, Antonieta (Hospital Universitari Vall d'Hebron) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tobiasson, Magnus (Karolinska Institutet (Estocolm, Suècia)) ;
Hellström-Lindberg, Eva (Karolinska Institutet (Estocolm, Suècia)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). [...]
2024 - 10.1158/2767-9764.CRC-23-0389
Cancer Research Communications, Vol. 4 Núm. 2 (2024)
|
|
|
7.
|
|
12 p, 6.3 MB |
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
/
Body, Simon (Normandie Univ) ;
Esteve-Arenys, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Miloudi, Hadjer (Normandie Univ) ;
Recasens-Zorzo, C.lara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Tchakarska, Guergana (McGill University Health Centre) ;
Moros, Alexandra (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bustany, Sophie (Normandie Univ) ;
Vidal-Crespo, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodriguez, Vanina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lavigne, Régis (Plateforme Protéomique - Protim. Biogenouest) ;
Com, Emmanuelle (Plateforme Protéomique - Protim. Biogenouest) ;
Casanova Rigat, Isolda (Institut d'Investigació Biomèdica Sant Pau) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Weigert, Oliver (Ludwig Maximilians University) ;
Sanjuan-Pla, Alejandra (Hospital Universitari i Politècnic La Fe (València)) ;
Menéndez Bujan, Pablo (Institució Catalana de Recerca i Estudis Avançats) ;
Marcq, Bénédicte (Centre Henri Becquerel) ;
Picquenot, Jean-Michel (Centre Henri Becquerel) ;
Pérez-Galán, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jardin, Fabrice (Centre Henri Becquerel) ;
Roué, Gaël (Hospital Universitari Vall d'Hebron) ;
Sola, Brigitte (Normandie Univ) ;
Universitat Autònoma de Barcelona
Mantle cell lymphoma (MCL) is a hematologic neoplasm characterised by the t(11;14)(q13;q32) translocation leading to aberrant cyclin D1 expression. The cell functions of cyclin D1 depend on its partners and/or subcellular distribution, resulting in different oncogenic properties. [...]
2017 - 10.1038/s41598-017-14222-1
Scientific reports, Vol. 7 Núm. 1 (january 2017) , p. 13946
|
|
|
8.
|
|
13 p, 2.5 MB |
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
/
Ribeiro, Marcelo Lima (Sao Francisco University Medical School. Laboratory of Immunopharmacology and Molecular Biology) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes Garau, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Miskin, Hari P. (TG Therapeutics (New York)) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Esteller, M. (Institució Catalana de Recerca i Estudis Avançats) ;
Normant, Emmanuel (TG Therapeutics (New York)) ;
Roué, Gaël (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory (R/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody. [...]
2023 - 10.3389/fimmu.2023.1130052
Frontiers in immunology, Vol. 14 (April 2023) , art. 1130052
|
|
|
9.
|
|
11 p, 1.4 MB |
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma
/
Ribeiro, Marcelo Lima (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sedó Mor, Alícia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Miskin, Hari (TG Therapeutics (Nova York)) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Normant, Emmanuel (TG Therapeutics (Nova York)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non-Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexplored. [...]
2021 - 10.1158/1078-0432.CCR-21-1067
Clinical Cancer Research, Vol. 27 (september 2021) , p. 6591-6601
|
|
|
10.
|
|
1 p, 80.2 KB |
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
/
Dlouhy, Ivan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Armengol, Marc Antoni (Universitat Autònoma de Barcelona) ;
Recasens-Zorzo, Clara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribeiro, Marcelo L. (Universidade São Francisco) ;
Pérez-Galán, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
López Guillermo, Armando (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2022 - 10.3324/haematol.2022.281988
Haematologica, Vol. 107 (december 2022) , p. 2990
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
